Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | CX-2009 |
Synonyms | |
Therapy Description |
CX-2009 is a probody drug conjugate consisting of the cytotoxic agent, maytansinoid DM4, and an antibody to the tumor associate antigen, CD166 (ALCAM), with a masking peptide that is cleaved by proteases specific to tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CX-2009 | CX2009|CX 2009|Praluzatamab ravtansine | CX-2009 (Praluzatamab ravtansine) is a probody drug conjugate consisting of the cytotoxic agent, maytansinoid DM4, and an antibody to the tumor associate antigen, CD166 (ALCAM), with a masking peptide that is cleaved by proteases specific to tumor cells (PMID: 32483421). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03149549 | Phase Ib/II | CX-2009 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | Completed | USA | 3 |
NCT04596150 | Phase II | CX-2009 CX-072 + CX-2009 | Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer | Recruiting | USA | 0 |